溶瘤腺病毒治疗肾癌的研究进展

我国肾癌发病率逐年上升。早期肾癌有治愈的可能，但晚期或转移性肾癌的治疗仍是一大难题。溶瘤腺病毒作为一种新型抗肿瘤制剂，具有选择性复制并杀伤肿瘤细胞的特点。近年来研究发现，溶瘤腺病毒对肾癌具有良好的抗肿瘤效果及安全性，联合放化疗治疗可以进一步提高疗效。以溶瘤腺病毒为载体的肾癌基因治疗也有广阔的应用前景。     

层面递进法激光腔内剜除高危前列腺增生的治疗体会

目的探讨1 470 nm激光剜除治疗高危前列腺增生的手术技巧及临床效果。 方法回顾分析2018年6月至2018年9月中山大学附属第三医院泌尿外科采用1 470 nm激光治疗共89例高危前列腺增生患者的临床资料，年龄平均（68±3）岁，前列腺体积（57.4±2.6）ml。所有患者均采用"寻找层面，先易后难，剜切结合"的层面递进法思路行激光腔内前列腺剜除术，比较患者术中及术后情况。 结果89例均顺利完成手术，与术前相比，术后3个月患者最大尿流率明显增加，[（6.9±2.1） ml/s vs（19.8±3.6） ml/s]。国际前列腺症状评分显著好转，[（24.6±1.7） vs（8.0±1.2）]。术中无输血、无电切综合征、无直肠和膀胱穿孔病例，无输尿管损伤、大出血、心脑血管意外等严重并发症发生。 结论层面递进法激光剜除技术构想对于高危前列腺增生外科包膜层面的寻找、减少术后并发症有独到优势，且易于掌握，或可为业界同行提供一个新的思路。     

分化型甲状腺癌患者撤除甲状腺素期间生活质量及影响因素分析

目的调查分化型甲状腺癌患者撤除甲状腺素期间生活质量状况,并分析影响因素。方法采用便利抽样法,选取浙江省某三级甲等医院266例患者作为研究对象,采用一般资料调查表、生活质量核心量表进行调查。结果患者撤除甲状腺素期间,生活质量高于其他肿瘤患者,但低于常模得分,差异均具有统计学意义(P<0.05)。年龄、碘治疗次数、疲乏、失眠、食欲减退、注意力减退是分化型甲状腺癌患者撤除甲状腺素期间生活质量的影响因素。结论分化型甲状腺癌患者撤除甲状腺素期间生活质量低于常模,且受多种因素影响。     

大数据在护理领域的应用进展

概述大数据及护理大数据的概念、特点,分析大数据在护理领域的应用现状,讨论其面临的挑战并提出应对策略,以期为大数据在护理领域的进一步发展提供参考。     

致心律失常性右室发育不良室性心动过速的电生理检查和外科治疗（附一例报告）

报告药物治疗无效、射频导管消融失败的致心律失常性右室发育不良（ＡＲＶＤ）顽固性室性心动过速（简称室速）１例患者，在电生理导引下行右室前游离壁隔离术治疗成功。术后随访７个月无室速发作，左室收缩功能正常。提示部分右室隔离术对有生命危险和药物治疗无效及射频导管消融失败的ＡＲＶＤ室速患者是安全、有效的     

氨茶碱伍用纳洛酮治疗早产儿原发性呼吸暂停疗效观察(附46例临床报告)

目的观察氨茶碱伍用纳洛酮治疗早产儿原发性呼吸暂停的临床疗效。方法将112例早产儿随机分为两组,对照组(66例)和观察组(46例),对照组及观察组均应用氨茶碱治疗呼吸暂停,观察组加用纳洛酮,首次按0.1mg/kg静脉侧入,继之以0.1mg/kg,以0.03～0.05mg/(kg·h)速度静脉泵入,连用3d。比较两组原发性呼吸暂停的时间和发生次数、心率、经皮血氧饱和度等的差异。结果两组呼吸暂停次数为(1.6±0.9)次/dvs(3.0±1.7)次/d及日均积分(1.7±1.3)分vs(3.6±2.4)分,观察组均明显减少,P<0.001和P<0.05;呼吸暂停的时间(18.6±3.5)svs(20.2±3.9)s,观察组明显缩短;SpO2(81.0±10.6)%vs(75.4±8.9)%及心率(91.2±12.6)次/minvs(84.6±14.3)次/min,观察组下降程度明显减轻(P<0.05)。治疗组总有效率明显优于对照组(χ2=8.47,P<0.01)。结论氨茶碱伍用纳洛酮治疗早产儿原发性呼吸暂停疗效显著。     

残胃癌的外科治疗(附26例临床分析)

多数学者认为 :残胃癌是指胃、十二指肠良性病变行胃大部切除术后或胃空肠吻合术等手术 5年以上残胃发生的癌[1] 。对于发生于胃癌术后的是否属于残胃癌 ,其时间间隔应为多少 ,仍有很大争议。我院自 1980年至 2 0 0 0年间共收残胃癌 2 6例 (同期收住的 11例胃癌术后出现的残胃癌未包括其内 ) ,现将 2 6例残胃癌的临床特点报告如下 :1　临床资料1)　一般资料 :本组残胃癌 2 6例 ,男 2 4例 ,女2例 ,年龄 38～ 76岁 ,平均年龄 5 9.3岁 ,男女比例为 12∶1,确诊前症状持续平均时间为 6 .8个月 ,5 0岁以上占 84 .6 % (2 2 / 2 4 )。吞咽不畅 8例(3…     

环戊硫酮治疗干眼的临床疗效评价

Objective To investigate anethol trithione therapic efficiency on dry eye. Methods It was a prospective random double-blind controlled study. Eighty cases diagnosed dry eye in Ocular Surface Out-patient Clinic of Xiamen University Affiliated Xiamen Eye Center from 2006 to 2008 were divided into two groups: anethol trithione group and control group, 40 cases in each group. Every group was then divided into two subgroups: weak dry eye subgroup, middle and severe dry eye subgroup. All groups had been added with 0.05% refresh drops. All patients had been detected and evaluated by subjective symptoms of dry eye, visual acuity,corneal fluorescent staining(F1), break-up time(BUT) and Schirmer Ⅰ test (SⅠT) at pre-therapy and 3,7,28 d of post-therapy. All groups had been compared and analyzed by F test and sample mean difference (SMD) or median difference (MD) comparison between pre-therapy and post-therapy. Results Except of tear and red eye, the other subjective symptoms of dry eye, F1, BUT and SⅠT of weak dry eye subgroup of both groups had been improved at 7 d after therapy. Only those of middle and severe dry eye subgroup of anethol trithione group had been improved at 7 d after therapy compared with those of pre-therapy: SMD=0.96 (visual tiredness), 1.26 (dry and unsmooth sensation), 0.82 (foreign body sensation), 1.28 (burning sensation), 1.05 (photophobia), 1.48 ( pain ) ; MD=0.30 (visual acuity), 4.00 (F1) ,5.00 (BUT), 5.00 (SⅠT) [F=15.30 (visual tiredness), 15.68 (dry and unsmooth sensation ), 13.56 (foreign body sensation), 20. 91 ( burning sensation ), 18.90 (photophobia), 27.22 ( pain ), 10.54 (visual acuity), 188.21 (F1) ,261.76 (BUT) ,269.05 (SⅠT) ;P<0. 05]. Those of middle and severe dry eye subgroup of control group hadn't significantly been improved at 28 d after therapy: SMD=0.10 (visual tiredness) ,0.16 (dry and unsmooth sensation) ,0.09 (foreign body sensation) ,0.38 ( burning sensation ), 0.24(photophobia) ,0.36 (pain) ,0.23 (red eye) ; MD=0.10 (visual acuity) ,0.50(F1) ,0.50(BUT), 0.50(SⅠT) [F=1.76 (visual tiredness), 1.61 (dry and unsmooth sensation), 1.02 (foreign body sensation),2.39 (burning sensation), 2.42 (photophobia), 2.73 ( pain ), 2.55 ( red eye ), 1.46 ( visual acuity) ,2.35 (F1) ,2.90 (BUT) ,2.76 (SⅠT) ; P>0.05]. SⅠT of anethol trithione group had been improved more significantly after therapy (F=13.77, P<0.05). Conclusion Anethol trithione could significantly improve middle and severe dry eye patients' symptoms and signs whose lacrimal gland function survival and it has clinical application value.